39 results about "MALE INFERTILITY DISORDERS" patented technology

The invention discloses a method for diagnosing male infertility, and discloses a biological marker indicating male infertility, a method for indentifying and detecting the biological marker indicating male infertility, and a kit for diagnosing or detecting male infertility. The method combined with seminal fluid routine inspection helps to realize the accurate diagnosis on male infertility.

Reagents, methods, and kits are described that are useful for fertility testing and that in many cases provides much faster, convenient and rapid determination of male infertility. The reagents described include properly glycosylated human ZP3, ZP2, ZP1, glycosylated peptides thereof, fusion proteins such as green fluorescent protein—ZP3, non-covalent complexes of ZP2 with ZP3, fusion protein of ZP2–ZP3, solid phase materials such as agarose beads coated with binding agents such as ZP3, and other artificial zona. Methods are provided that, in many cases convert a complex biological event into a well defined biochemical binding event based on one or more of the reagents. Such methods are much easier to set up and monitor, allowing more convenient and inexpensive diagnostic testing for male fertility. The acrosome reaction is detected in other embodiments by virtue of quantitating one or more released substances. Kits are further provided that contain one or more reagents useful for testing at a diagnostic laboratory or other facility.

The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a leukotriene receptor antagonist. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a CFTR potentiator or a CFTR corrector.

A profertility composition for administration to infertile men with sperm oxidative stress is disclosed. The composition comprises a unique combination of a pharmaceutically acceptable vitamin E, vitamin C, selenium, zinc, folic acid, lycopene and at least one carnitine source.

The diagnosis of male infertility is based predominantly on the results of standard semen analysis for concentration, total motility, progressive motility, volume, pH, viscosity and / or morphology. When sperm enter the female reproductive tract, they must undergo a series of physiological changes, known as capacitation, in order to fertilize an egg. This process involves plasma membrane changes that occur in response to stimuli within the female tract. These changes include removal of sterols and redistribution of the ganglioside GM1. Semen analysis identifies only half the cases of male infertility due to standard semen analysis providing little information on sperm functional competence. Previous data demonstrated that localization of the ganglioside, GM1, identifies sub-populations of sperm capable of undergoing the functional maturation process known as capacitation and tracks strongly with fertility.

The invention relates to a medicine composition for treating male infertility and particularly relates to a medicine composition for treating male oligospermia / asthenozoospermia infertility. The traditional Chinese medicine composition contains the following ingredients: (a) radix rehmanniae praeparata, (b) rhizoma polygonati preparata, (c) cistanche deserticola and (d) bitter melon slices.

The invention provides a traditional Chinese medicine composition and its preparation method and application, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for treating male infertility provided by the invention includes Rehmannia glutinosa, Cuscuta, Astragalus, Epimedium, Salvia miltiorrhiza, Achyranthes achyranthes, leech, Milletah, and Passepartout. The traditional Chinese medicine composition provided by the invention can significantly improve sperm motility, activity rate and sperm linear motion speed, and its clinical curative effect is better than that of conventional Chinese patent medicines. It provides an effective prescription for the clinical treatment of idiopathic asthenozoospermia and male infertility. The drug has a wide range of drug sources, low price, no toxic side effects, reasonable prescription, good curative effect, quick effect, economic benefits, not easy to relapse and no damage to the human body, etc., and is worthy of popularization and application. The preparation method of the traditional Chinese medicine composition provided by the present invention uses the composition of the present invention as a raw material, and adopts a physical method of decoction to extract and utilize the active ingredients in the composition, and has the advantages of simple preparation method and quick drug effect.

The invention provides a traditional Chinese medicine composition for treating male infertility and a preparation process thereof, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition for treating male infertility comprises the following raw materials in parts by weight: 12 to 22 parts of spermatogenesis promoting component, 6 to 12 parts of alpha receptor blocker component, 10 to 20 parts of sperm active component, 6 to 12 parts of semen cuscutae, 5 to 12 parts of herba cistanche, 6 to 20 parts of fructus lycii, 6 to 12 parts of fructus corni, 1 to 5 parts of cornu cervi pantotrichum and 5 to 10 parts of herba cynomorii. The traditional Chinese medicine composition for treating male infertility has an excellent treatment effect on infertility caused by male oligospermia and asthenospermia, and has extremely small side effects. In addition, the invention further provides a preparation process of the traditional Chinese medicine composition for treating male infertility. Effective substances of all the components of the traditional Chinese medicine composition for treating male infertility are extracted through the process, the effective components are reserved, and the treatment effect is improved.

The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a leukotriene receptor antagonist. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a CFTR potentiator or a CFTR corrector.

The invention provides a decoction for promoting the production of sperms. The decoction has the function of reinforcing kidney to replenish essence and is extremely good in treating effect for male infertility caused by spermatogenic failure. As a traditional Chinese medicine composition, the decoction is prepared from the following more than ten crude drugs by weight: epimedium herbs, radix polygoni multiflori preparata, radix rehmanniae preparata, astragalus, angelica sinensis, cistanche, tuckahoe, radix achyranthis bidentatae, barbary wolfberry fruits, semen cuscutae, cnidium monnieri, schisandra chinensis, placenta hominis and the like. The decoction is capable of reinforcing kidney to replenish essence for the male, rapid in taking curative effects for male infertility caused by spermatogenic failure and free of toxic or side effect for human bodies due to the addition of natural traditional Chinese medicine components. According to the formula, the decoction has the effects of strengthening sperms and effectively increasing the quantity of the sperms.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for treating male infertility. The traditional Chinese medicine composition is composed of eight traditional Chinese medicines, namely, astragalus membranaceus, talcum, spica prunellae and the like. The traditional Chinese medicine composition has functions of tonifying kidney qi to alleviate water retention and softening hardness to dissipate stagnation, and can be used for effectively treating the male infertility.

Methods and systems are provided for diagnosing male infertility relating to inadequate production of phosphatidic acid and are complementary to the routine tests, assessing sperm count, motility, viability, head morphology, and white blood cell count. Additional therapeutic methods, compositions and dosage forms are provided for treating male infertility that is related to inadequate production of phosphatidic acid. Such therapeutic approaches involve the use of phosphatidic acid or at least one of its precursors in the sperm intracellular signaling pathway.

Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-4 (alpha and beta) and TREM-5 are disclosed. TREM-4 is a transmembrane glycoprotein expressed selectively in the endothelium of capillaries, in the heart and in the testis. Use of TREM-4 in treatment and diagnosis of various inflammatory diseases and heart diseases and male infertility are also provided. TREM-5 is also a transmembrane glycoprotein expressed selectively in bone marrow-derived population of leukocytes, in particular dendritic cells, and may be upregulated in certain conditions, such as cell activation, inflammation or aberrant dendritic cell function. Blockade of TREM-5 with monoclonal antibodies or soluble TREM-5-HuIgG fusion protein may reduce or block skin diseases or dendritic cell associated disorders.

The invention discloses a traditional Chinese medicinal composition for treating male infertility and a preparation method of the traditional Chinese medicinal composition. The traditional Chinese medicinal composition is characterized by comprising, by weight, 20-30 parts of prepared rehmannia roots, 6-15 parts of pulp of dogwood fruits, 20-30 parts of astragalus membranaceus, 6-9 parts of angelica sinensis, 10-20 parts of human placentas, 6-12 parts of stiff silkworms, 20-35 parts of silkworm excrement, 10-15 parts of rhizoma curculiginis, 10-15 parts of herba epimedii 15-25 parts of semen cuscutae, 20-40 parts of mulberry fruits, 9-18 parts of semen allii tuberosi, 3-9 parts of the root of three-nerved spicebush, 20-25 parts of cherokee rose fruits, 10-15 parts of rhizoma cibotii and 5-9 parts of cape jasmine. The traditional Chinese medicinal composition has the advantages that the prepared rehmannia roots serve as a monarch drug, the pulp of the dogwood fruits and the astragalus membranaceus serve as ministerial drugs, the angelica sinensis, the human placentas, the stiff silkworms, the silkworm excrement, the rhizoma curculiginis, the herba epimedii, the semen cuscutae, the mulberry fruits, the semen allii tuberosi, the root of three-nerved spicebush and the cherokee rose fruits serve as adjuvant drugs to purge the pathogenic fire and relieving restlessness, and the capejasmines serve as an envoy drug, which is free of toxic and side effects, so that the effect of tonifying yin and yang, replenishing qi and enriching the blood is achieved, and the traditional Chinesemedicinal composition can treat kidney diseases such as kidney deficiency, male sexual dysfunction and female sterility.

The invention discloses a medicine for treating gynecological diseases and andrological diseases. The medicine is prepared from cassia twigs, rhizoma sparganic, curcuma zedoary, leeches, earthworms, sargentgloryvine stems, kelp, herba patriniae, polygonum cuspidatum, myrrh, radix aconiti carmichaeli, liquidambar formosana hance, cowherb seeds, asarum, oldenlandia diffusa, fructus cnidii and honey. The medicine for treating gynecological diseases and andrological diseases has the advantages that through the mutual synergistic effect of the medicines, the medicine can be used for treating infertility, abnormal leucorrhea, annexitis, pelvic inflammation, vaginitis, cervicitis, cervical erosion, hysteromyoma, ovarian cyst, uterine prolapse, tubal nowhere, menstrual stomachache, menstrual disorder, amenorrhea, endocrine dyscrasia, habitual abortion, waist soreness and pain after parturition, incomplete lochia and bleeding, sexual apathy, congenital uterine and ovarian dysplasia atrophy, endometriosis and the like, and also can be used for treating male prostatitis, prostatic hyperplasia calcification, varicocele, non-liquefaction of sperms, asthenospermia, oligospermia, testicular dysplasia, epididymitis and other male infertility and other male diseases.

The invention relates to a preparation method and application of a colorimetric array sensor of a zirconium-based metal-organic framework and single-stranded DNA modified gold nanoparticles. Six different single-stranded DNA sequences were designed to modify the surface of gold nanoparticles to form unique sensor recognition elements. The new material zirconium-based metal-organic framework can bind and precipitate single-stranded DNA sequence modification on gold nanoparticles through different intermolecular forces. After adding certain proteins or semen samples, their binding force can be accelerated or slowed down, affecting It aggregates to produce a detectable signal. Therefore, we can consider that these recognition elements have different interactions with different targets, and we can detect different targets obviously by analyzing the colorimetric response of each recognition element in combination. The invention can be used for the colorimetric array analysis of various proteins and male semen simply and efficiently, and provides detection basis for the analysis of male infertility.

The invention discloses a Miao nationality medicine for treating male infertility. The Miao nationality medicine is prepared from the following medicinal materials in parts by mass: 13-19 parts of sargentodoxa cuneata, 13-19 parts of gorgon euryale seeds, 7-13 parts of semen cuscutae, 7-13 parts of schisandra chinensis, 7-13 parts of cornus officinalis, 13-19 parts of entada phaseoloides and 13-19parts of raspberries. The Miao nationality medicine is ground into powder and taken with light salt water or honey. Through reasonable compatibility of the components, the Miao nationality medicine has the effects of nourishing yin, enriching blood and boosting essence and seeds, and is suitable for male infertility caused by kidney essence deficiency and qi-blood deficiency; and one month is a course of treatment, the effective rate is 81% or above, and no other side effects are generated in the medicine taking process.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for treating spleen deficiency type male infertility. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 to 60 parts of American ginseng extract, 30 to 80 parts of radix astragali seu hedysari extract, 50 to 80 parts of semen coicis extract, 30 to 45 parts of berchemia floribunda root extract, 9 to 18 parts of gossypium hirsutum extract, 3 to 12 parts of pimpinella thellungiana extract, 6 to 15 parts of pseudostellaria heterophylla extract, 6 to 15 parts of palm sedge extract, 3 to 12 parts of liquorice root extract, 9 to 30 parts of manglietia fordiana fruit extract, 9 to 15 parts of linseed extract, 4 to 6 parts of radix bupleuri extract and 3 to 6 parts of pericarpium citri reticulatae extract. The invention further discloses a preparation method of the traditional Chinesemedicine composition for treating the spleen deficiency type male infertility. The preparation method comprises the following steps: S1, preparing traditional Chinese medicine extract; S2, preparing amixing container; S3, mixing the raw materials; and S4, packaging in vacuum. The traditional Chinese medicine composition provided by the invention can be used for remarkably treating the spleen deficiency type male infertility and has small side effect and small recurrence possibility.

The invention relates to a preparation method and application of a colorimetric array sensor adopting a zirconium-based metal organic framework and single-stranded DNA modified gold nanoparticles. Sixdifferent single-stranded DNA sequences are designed to modify the surfaces of gold nanoparticles, so that unique sensor recognition elements are formed. Through different intermolecular forces, thenovel material, namely, the zirconium-based metal organic framework can be combined with or precipitate the gold nanoparticles modified by the single-stranded DNA sequences, after some protein or semen samples are added, the binding force can be accelerated or slowed down, the aggregation behavior is influenced, and thus a detectable signal is generated. Therefore, the recognition elements have different interactions when binding with different targets, and by combined analysis of the colorimetric response of each recognition element, different targets can be detected obviously. The colorimetric array sensor can be simply and efficiently used for colorimetric array analysis of various proteins and male seminal fluid, and a detection basis is provided for analysis of male infertility.

The present disclosure generally relates to the field of infertility, and in particular male infertility. Accordingly, the present disclosure provides for compositions and methods for managing male infertility, caused by azoospermia. More particularly, the present disclosure provides a therapeutic composition comprising a platelet rich plasma (PRP) or a growth factor concentrate derived therefrom and a thermoresponsive polymer. The present disclosure also relates to the compositions of PRP and the concentrate themselves. Consequently, methods to obtain the said compositions, along with therapeutic applications for treatment of azoospermia are also provided.

Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.

The present disclosure generally relates to the field of infertility, and in particular male infertility. Accordingly, the present disclosure provides for compositions and methods for managing male infertility, caused by poor semen quality. More particularly, the present disclosure provides a therapeutic composition comprising a platelet rich plasma (PRP) or a growth factor concentrate derived therefrom and a thermoresponsive polymer. The present disclosure also relates to the compositions of PRP and the concentrate themselves. Consequently, methods to obtain the said compositions, along with therapeutic applications for treatment of infertility caused by poor semen quality are also provided.

The invention discloses the use of substance P in preparing medicine for treating male infertility. The present invention treats the azoospermia mouse model with substance P, and finds that substance P can effectively improve the spermatogenic function of the azoospermia mouse model induced by busulfan, and further confirms that substance P promotes the proliferation of spermatogenic cells To improve spermatogenesis; the invention provides new ideas and theoretical support for the treatment of male infertility.

The present invention relates to a pharmaceutical composition including vitrified periodontal tissue-derived mesenchymal stem cells for prevention or treatment of male infertility. The pharmaceutical composition for prevention or treatment of male infertility according to the present invention recovers sex hormone levels in seminiferous tubules of atrophic testes and blood to normal levels through improvement in the activity of lipid metabolism enzymes in the liver, thereby exhibiting remarkable prophylactic and therapeutic effects on male infertility. In addition, the periodontal tissue-derived mesenchymal stem cells which are an active ingredient in the present invention can be obtained in the most non-invasive manner and as such, are expected to be advantageously used as a cell therapy product for male infertility.

The invention relates to a traditional Chinese medicine prescription for treating male infertility, which consists of male silkworm moth, cannon shell beads, tortoise shell, agarwood, velvet antler slices, rehmannia glutinosa, dogwood, Cistanche deserticola, epimedium, paeonol bark, Phellodendron cypress, plantain and wolfberry. It is composed of sixteen kinds of herbs including Semen Seed, Red Peony Root, Paeonia lucidum and Poria Cocos. It has been confirmed through pharmacological experimental studies that the present invention has the effects of nourishing yin and clearing heat, replenishing the kidneys and promoting spermatogenesis, strengthening the spleen and removing dampness, promoting blood circulation and removing blood stasis; it can enhance the number of testicles, epididymal seminal vesicles, prostate and sperm, and has the effect of restoring testicular spermatogenesis. Function: It has a significant effect in treating abnormal sperm quality and semen volume due to kidney yin deficiency, immune infertility and unexplained infertility.

The invention discloses a pharmaceutical preparation for treating male infertility and application thereof. The pharmaceutical preparation is prepared from an active ingredient and pharmaceutically acceptable auxiliary materials, and the active ingredient is prepared from, by weight, 36-48 parts of horsetail, 36-48 parts of root of common lantana, 8-16 parts of Siberian elm bark, 6-10 parts of bark of eucommia and 6-10 parts of Fructus cnidii through decocting with water. Animal experiment and clinical experiment studies show that the pharmaceutical preparation can inhibit nonspecific immune injury and reduce tissue pathological injury and can be used for treating infertility of male patients with positive AsAb.